Home>Topics>Companies>Johnson & Johnson

Johnson & Johnson JNJ

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UK watchdog says Reckitt's K-Y buy could hurt competition

      Headlines

      Fri, 22 May 2015

      LONDON, May 22 (Reuters) - Reckitt Benckiser Group's proposed purchase of K-Y personal lubricants from Johnson & Johnson could lead to less competition and higher prices, Britain's competition watchdog said on Friday.

    2. UPDATE 2- J & J to submit at least 10 new drugs for approval by 2019

      Headlines

      Wed, 20 May 2015

      May 20 (Reuters) - U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to...

    3. CORRECTED-UPDATE 1-Achillion partners with J & J to develop hep C drugs (May 19)

      Headlines

      Wed, 20 May 2015

      May 19 (Reuters) - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

    4. J & J says will submit 10 medicines to regulators by 2019

      Headlines

      Wed, 20 May 2015

      NEW YORK, May 20 (Reuters) - Drugmaker Johnson & Johnson said on Wednesday that it would submit 10 new medicines to regulators by 2019, forecasting that many of the drugs in its research and development pipeline will have more than $1 billion in peak annual sales.

    5. UPDATE 1-Achillion partners with J & J to develop hep C drugs

      Headlines

      Tue, 19 May 2015

      May 19 (Reuters) - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

    6. Achillion partners with J & J to develop hep C drugs

      Headlines

      Tue, 19 May 2015

      May 19 (Reuters) - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market one or more of its hepatitis C drugs.

    7. FDA approves longer-acting version of J & J's schizophrenia drug

      Headlines

      Tue, 19 May 2015

      May 19 (Reuters) - The U.S. Food and Drug Administration approved a longer-acting version of Johnson & Johnson 's schizophrenia treatment, developed by the company's Janssen Pharmaceuticals unit.

    8. Ultimate Stock-Pickers’ Top 10 High-Conviction and New-Money Purchases

      Headlines

      Tue, 19 May 2015

      also note that Danaher DHR and Johnson & Johnson JNJ were high-conviction new-money ..... As for wide-moat rated Johnson & Johnson , it was a meaningful new-money ..... Jensen Quality Growth Fund, Johnson & Johnson . JNJ is a globally diversified healthcare

    9. UPDATE 2-U.S. FDA warns on newer class of type 2 diabetes drugs

      Headlines

      Fri, 15 May 2015

      May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership...

    10. U.S. FDA warns on newer class of type 2 diabetes drugs

      Headlines

      Fri, 15 May 2015

      May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership...

    « Prev12345Next »
    Content Partners